Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | POLD1 | P28340 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378754 | 0.91 | TK1 (0.47) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL14378755 | 0.91 | TK1 (0.47) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL6689098 | 0.91 | TK1 (0.53) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL14378706 | 0.89 | TK1 (0.49) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL7044279 | 0.85 | POLB (0.58) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL16315911 | 0.83 | ALDH1A1 (0.53) | TK1POLBBCHEP2RY6P2RY14 | |
| SCHEMBL14378753 | 0.83 | POLB (0.69) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL2696427 | 0.83 | TK1 (0.54) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL6420653 | 0.82 | TK1 (0.58) | TK1POLBPOLA1POLD1BCHE | |
| SCHEMBL23440065 | 0.81 | TK1 (0.67) | TK1POLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK1 62/4885POLB 623/4885POLA1 909/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | TK1 62/4885POLB 623/4885POLA1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.